ArticleScientific reports2017

The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome.

Cathryn J Kurkjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.